1. Home
  2. LCFY vs NXL Comparison

LCFY vs NXL Comparison

Compare LCFY & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.30

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.34

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
NXL
Founded
2009
2010
Country
Australia
United States
Employees
18
8
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCFY
NXL
Price
$4.30
$0.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.8K
195.5K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.33
52 Week High
$13.98
$2.00

Technical Indicators

Market Signals
Indicator
LCFY
NXL
Relative Strength Index (RSI) 45.30 39.12
Support Level $4.07 N/A
Resistance Level $4.84 $0.46
Average True Range (ATR) 0.19 0.03
MACD -0.05 -0.01
Stochastic Oscillator 23.53 2.74

Price Performance

Historical Comparison
LCFY
NXL

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: